Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02467907
Recruitment Status : Completed
First Posted : June 10, 2015
Last Update Posted : June 3, 2019
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study is to assess safety as defined by the frequency and severity of gastrointestinal (GI) perforation/fistula, GI-vaginal fistula and genitourinary (GU) fistula in participants treated with bevacizumab 15 milligrams per kilogram (mg/kg) in combination with paclitaxel and carboplatin, all repeated every 3 weeks, for recurrent, persistent or metastatic cervical cancer. In addition, this study will include evaluation of the overall safety profile of bevacizumab in combination with paclitaxel and carboplatin in this setting, assessment of GI perforation/fistula, GI-vaginal fistula and GU fistula events over time, and evaluation of efficacy.

Condition or disease Intervention/treatment Phase
Cervical Cancer Drug: Bevacizumab Drug: Carboplatin Drug: Paclitaxel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 152 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Open-Label Single-Arm Phase II Study Evaluating the Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Metastatic, Recurrent or Persistent Cervical Cancer
Actual Study Start Date : July 28, 2015
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : January 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arm Intervention/treatment
Experimental: Bevacizumab in Combination with Carboplatin and Paclitaxel
Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.
Drug: Bevacizumab
Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
Other Name: Avastin, RO4876646

Drug: Carboplatin
Administration of carboplatin at 5 milligrams per milliliter*minute (mg/mL*min) on Day 1 every 3 weeks for at least 6 cycles

Drug: Paclitaxel
Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m^2) on Day 1 every 3 weeks for at least 6 cycles




Primary Outcome Measures :
  1. Percentage of Participants with GI Perforation/Fistula Events by Grade According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 [ Time Frame: Baseline up to 24 months ]
  2. Percentage of Participants with GI-Vaginal Fistula Events by Grade According to NCI-CTCAE Version 4.0 [ Time Frame: Baseline up to 24 months ]
  3. Percentage of Participants with GU Fistula Events by Grade According to NCI-CTCAE Version 4.0 [ Time Frame: Baseline up to 24 months ]

Secondary Outcome Measures :
  1. Time to First GI Perforation/Fistula [ Time Frame: Baseline up to 24 months ]
  2. Time to First GI-Vaginal Fistula [ Time Frame: Baseline up to 24 months ]
  3. Time to First GU Fistula [ Time Frame: Baseline up to 24 months ]
  4. Dose Intensity (Ratio of Actual Dose Administered Versus Intended Dose) for Bevacizumab During the Treatment Period [ Time Frame: Baseline up to 24 months ]
  5. Dose Intensity (Ratio of Actual Dose Administered Versus Intended Dose) for Carboplatin During the Treatment Period [ Time Frame: Baseline up to 24 months ]
  6. Dose Intensity (Ratio of Actual Dose Administered Versus Intended Dose) for Paclitaxel During the Treatment Period [ Time Frame: Baseline up to 24 months ]
  7. Duration of Treatment for Bevacizumab [ Time Frame: Baseline up to 24 months ]
  8. Duration of Treatment for Carboplatin [ Time Frame: Baseline up to 24 months ]
  9. Duration of Treatment for Paclitaxel [ Time Frame: Baseline up to 24 months ]
  10. Percentage of Participants with Adverse Events (AEs) [ Time Frame: Baseline up to 24 months ]
  11. Percentage of Participants with Serious Adverse Events (SAEs) [ Time Frame: Baseline up to 24 months ]
  12. Percentage of Participants with Adverse Events of Special Interest (AESIs) [ Time Frame: Baseline up to 24 months ]
  13. Percentage of Participants with AEs Leading to Treatment Interruption or Permanent discontinuation [ Time Frame: Baseline up to 24 months ]
  14. Percentage of Deaths Causally Related to Treatment [ Time Frame: Baseline up to 24 months ]
  15. Progression-Free Survival (PFS) According to Response Evaluation Criteria for Solid Tumors (RECIST) Version 1.1 [ Time Frame: Baseline up to 24 months ]
  16. Overall Survival (OS) [ Time Frame: Baseline up to 24 months ]
  17. Percentage of Participants with a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.1 [ Time Frame: Baseline up to 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Life expectancy greater than or equal to (>=3) months
  • For women who are not postmenopausal or surgically sterile, agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of less than (<) 1 percent (%) per year during the treatment period and for at least 6 months after the last dose of study drug
  • Distant metastatic, recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy
  • Either measurable or non-measurable disease. If disease is non-measurable or limited to the radiation field, a biopsy or fine-needle aspiration is required to confirm malignancy
  • Eligible for carboplatin and paclitaxel chemotherapy in accordance with local standards of care
  • Adequate hematological, renal and hepatic function
  • Normal blood coagulation parameters
  • Recovered (to Grade less than or equal to [<=] 1) from the effects of prior surgery, radiation therapy or chemoradiotherapy

Exclusion Criteria:

  • Pregnant or lactating
  • History of other malignancy within 5 years before screening, except for non-melanoma skin carcinoma
  • Ongoing disease involving the bladder or rectum at screening/baseline. In participants with pelvic disease, absence of tumor in the bladder or rectal mucosa must be demonstrated by magnetic resonance imaging (MRI) (preferred method, or endoscopy/cystoscopy if MRI is not easily accessible) within 28 days before enrolment
  • Evidence of abdominal free air
  • Bilateral hydronephrosis
  • Untreated central nervous system (CNS) metastases
  • Prior chemotherapy for recurrent, persistent or metastatic cervical cancer. Prior adjuvant or neoadjuvant chemotherapy for Stage I-IVA disease (i.e. for non-metastatic disease) is permitted if completed greater than (>) 6 months before first study dose
  • Prior chemoradiation within the 3 months preceding first study dose
  • Prior radiotherapy delivered using cobalt
  • Prior or current bevacizumab or other anti-angiogenic treatment
  • Requirement for treatment with any medicinal product that contraindicates the use of any of the study drugs, may interfere with the planned treatment, affects participant compliance or puts the participant at high risk for treatment-related complications
  • Treatment with another investigational agent within 28 days or 2 investigational agent half-lives before first study dose
  • Major surgical procedure, open biopsy or significant traumatic injury within 28 days before the first dose of bevacizumab or anticipation of the need for major surgery during the course of study treatment
  • Minor surgical procedure within 2 days before the first dose of study drug
  • Any prior history of fistula or GI perforation
  • Known hypersensitivity to bevacizumab or any of its excipients, Chinese hamster ovary cell products or other recombinant human or humanized antibodies to any planned chemotherapy
  • Active GI bleeding or ulcer
  • Uncontrolled hypertension
  • Clinically significant active cardiovascular disease
  • National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0, Grade greater than or equal to (>=) 2 peripheral vascular disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02467907


  Show 43 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02467907     History of Changes
Other Study ID Numbers: MO29594
2014-005491-28 ( EudraCT Number )
First Posted: June 10, 2015    Key Record Dates
Last Update Posted: June 3, 2019
Last Verified: May 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Paclitaxel
Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors